Erratum: Phospho-Smad1 modulation by Nedd4 E3 ligase in BMP/TGF-β signaling (Journal of Bone and Mineral Research (2011) 26 (1411-1424) DOI:10.1002/jbmr.348);Phospho-Smad1 modulation by nedd4 e3 ligase in BMP/TGF-β signaling

Journal of Bone and Mineral Research

Volumn 26, Issue 7, 2011, Pages 1411-1424

  Kim, Byung Gyu ^a,c   Lee, Ji Hyun ^a,c   Yasuda, Jiro ^b,c   Ryoo, Hyun Mo ^b,c   Cho, Je Yoel ^a,c  

^a Kyungpook National University   (South Korea)

^b NATIONAL RESEARCH INSTITUTE OF POLICE SCIENCE   (Japan)

^c Seoul National University   (South Korea)

Author keywords

BMP TGF ; Nedd4; Nonosseous Calcification; Smad

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; PROTEASOME; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN PROTEIN LIGASE NEDD4;

ANIMAL CELL; ARTICLE; CALCIFICATION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOSARCOMA CELL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 79959492746     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1584     Document Type: Erratum

References (70)

1. Massague J, Blain SW, Lo RS,. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000; 103: 295-309.
2. Kitisin K, Saha T, Blake T, et al. TGF-β signaling in development. Sci STKE. 2007; 399: 1.
3. Roussa E, Wiehle M, Dunker N, Becker-Katins S, Oehlke O, Krieglstein K,. Transforming growth factor β is required for differentiation of mouse mesencephalic progenitors into dopaminergic neurons in vitro and in vivo: ectopic induction in dorsal mesencephalon. Stem Cells. 2006; 24: 2120-2129. (Pubitemid 44477137)
4. Shah AH, Tabayoyong WB, Kundu SD, et al. Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 2002; 62: 7135-7138. (Pubitemid 36025224)
5. Mishra L, Derynck R, Mishra B,. Transforming growth factor-β signaling in stem cells and cancer. Science. 2005; 310: 68-71. (Pubitemid 41434534)
6. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA,. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24: 99-146.
7. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001; 345: 325-334. (Pubitemid 32703235)
8. Liu D, Wang J, Kinzel B, et al. Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood. 2007; 110: 1502-1510. (Pubitemid 47443965)
9. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M,. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum. 2006; 54: 3011-3021. (Pubitemid 44497783)
10. Chen Y, Shi-wen X, Eastwood M, et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 2006; 54: 1309-1316. (Pubitemid 43672944)
11. Thomas JT, Lin K, Nandedkar M, Camargo M, Cervenka J, Luyten FP,. A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. Nat Genet 1996; 12: 315-317.
12. Eisman JA,. Genetics of osteoporosis. Endocr Rev. 1999; 20: 788-804. (Pubitemid 30647074)
13. Kaplan FS, Pignolo RJ, Shore EM,. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 2009; 20: 399-407.
14. Reddi AH,. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev. 1997; 8: 11-20. (Pubitemid 27214686)
15. Senta H, Park H, Bergeron E, et al. Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations. Cytokine Growth Factor Rev. 2009; 20: 213-222.
16. Janssens K, ten Dijke P, Janssens S, Van Hul W,. Transforming growth factor-beta1 to the bone. Endocr Rev. 2005; 26: 743-774.
17. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15: 757-765.
18. Chung CY, Iida-Klein A, Wyatt LE, et al. Serial passage of MC3T3-E1cells alters osteoblastic function and responsiveness to transforming growth factor-beta1 and bone morphogenetic protein-2. Biochem Biophys Res Commun. 1999; 265: 246-251.
19. Spinella-Jaegle S, Roman-Roman S, Faucheu C, et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. Bone. 2001; 29: 323-330. (Pubitemid 32930058)
20. Lee MH, Kim YJ, Kim HJ, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem. 2003; 278: 34387-34394.
21. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K,. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. Embo J. 2004; 23: 552-563. (Pubitemid 38282387)
22. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol. 2000; 20: 8783-8792.
23. Ryoo HM, Lee MH, Kim YJ,. Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene. 2006; 366: 51-57.
24. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R,. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. Embo J. 2001; 20: 2254-2272. (Pubitemid 32410595)
25. Kang JS, Alliston T, Delston R, Derynck R,. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. Embo J. 2005; 24: 2543-2555. (Pubitemid 41076311)
26. Li TF, Darowish M, Zuscik MJ, et al. Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J Bone Miner Res. 2006; 21: 4-16. (Pubitemid 43023222)
27. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003; 9: 964-968. (Pubitemid 36889942)
28. Yang YL, Liu YS, Chuang LY, et al. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors. Endocrinology. 2009; 150: 727-740.
29. Shi Y, Massague J,. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113: 685-700. (Pubitemid 36724933)
30. Attisano L, Wrana JL,. Signal transduction by the TGF-beta superfamily. Science. 2002; 296: 1646-1647.
31. Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009; 119: 566-576.
32. Lee NY, Kirkbride KC, Sheu RD, Blobe GC,. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell. 2009; 20: 4362-4370.
33. Lee NY, Ray B, How T, Blobe GC,. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem. 2008; 283: 32527-32533.
34. Blaney Davidson EN, Remst DF, Vitters EL, et al. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. J Immunol. 2009; 182: 7937-7945.
35. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M,. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem. 2007; 282: 10405-10413. (Pubitemid 47093454)
36. Wrighton KH, Lin X, Feng XH,. Phospho-control of TGF-beta superfamily signaling. Cell Res. 2009; 19: 8-20.
37. Inoue Y, Imamura T,. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008; 99: 2107-2112.
38. Chen HB, Shen J, Ip YT, Xu L,. Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev. 2006; 20: 648-653.
39. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH,. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 1999; 400: 687-693.
40. Ogunjimi AA, Briant DJ, Pece-Barbara N, et al. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol Cell. 2005; 19: 297-308. (Pubitemid 41074886)
41. Kuratomi G, Komuro A, Goto K, et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J. 2005; 386 (Pt 3): 461-470. (Pubitemid 40445870)
42. Kim BG, Kim HJ, Park HJ, et al. Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways. Proteomics. 2006; 6: 1166-1174.
43. Kim BG, Lee JH, Ahn JM, et al. 'Two-stage double-technique hybrid (TSDTH)' identification strategy for the analysis of BMP2-induced transdifferentiation of premyoblast C2C12cells to osteoblast. J Proteome Res. 2009; 8: 4441-4454.
44. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007; 110: 334-338. (Pubitemid 47026851)
45. Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008; 118: 491-504. (Pubitemid 351206540)
46. Topaz O, Indelman M, Chefetz I, et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet. 2006; 79: 759-764. (Pubitemid 44452755)
47. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL,. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest. 1994; 93: 2106-2113.
48. Ingham RJ, Gish G, Pawson T,. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene. 2004; 23: 1972-1984. (Pubitemid 38496727)
49. Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J,. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell. 2007; 25: 441-454. (Pubitemid 46199289)
50. Colland F, Jacq X, Trouplin V, et al. Functional proteomics mapping of a human signaling pathway. Genome Res. 2004; 14: 1324-1332. (Pubitemid 39029229)
51. Weston AD, Underhill TM,. Analysis of Nedd4 expression during skeletal development in the mouse limb. Mech Dev. 2000; 94: 247-250. (Pubitemid 30332410)
52. Koncarevic A, Jackman RW, Kandarian SC,. The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension. Faseb J. 2007; 21: 427-437. (Pubitemid 46213490)
53. Liu Y, Oppenheim RW, Sugiura Y, Lin W,. Abnormal development of the neuromuscular junction in Nedd4-deficient mice. Dev Biol. 2009; 330: 153-166.
54. Gao S, Alarcon C, Sapkota G, et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell. 2009; 36: 457-468.
55. Kumar S, Harvey KF, Kinoshita M, Copeland NG, Noda M, Jenkins NA,. cDNA cloning, expression analysis, and mapping of the mouse Nedd4 gene. Genomics. 1997; 40: 435-443. (Pubitemid 27136996)
56. Anan T, Nagata Y, Koga H, et al. Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. Genes Cells. 1998; 3: 751-763. (Pubitemid 29038094)
57. Wang W, Zhou W, Jiang L, et al. Mutation analysis of SCNN1B in a family with Liddle's syndrome. Endocrine. 2006; 29: 385-390. (Pubitemid 44358825)
58. Fotia AB, Ekberg J, Adams DJ, Cook DI, Poronnik P, Kumar S,. Regulation of neuronal voltage-gated sodium channels by the ubiquitin-protein ligases Nedd4 and Nedd 4-2. J Biol Chem. 2004; 279: 28930-28935. (Pubitemid 38915761)
59. Yasuda J, Nakao M, Kawaoka Y, Shida H,. Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol. 2003; 77: 9987-9992. (Pubitemid 37122080)
60. Leykauf K, Salek M, Bomke J, et al. Ubiquitin protein ligase Nedd4 binds to connexin43 by a phosphorylation-modulated process. J Cell Sci. 2006; 119 (Pt 17): 3634-3642. (Pubitemid 44501867)
61. Yang B, Gay DL, MacLeod MK, et al. Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cells. Nat Immunol. 2008; 9: 1356-1363.
62. Marmor MD, Yarden Y,. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004; 23: 2057-2070. (Pubitemid 38496735)
63. Chen C, Matesic LE,. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 2007.
64. Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007; 128: 129-139. (Pubitemid 46048884)
65. Fouladkou F, Landry T, Kawabe H, et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A. 2008; 105: 8585-8590. (Pubitemid 351987724)
66. Miyazono K, Maeda S, Imamura T,. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005; 16: 251-263. (Pubitemid 40910315)
67. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003; 12: 817-828. (Pubitemid 37352776)
68. Wrighton KH, Lin X, Yu PB, Feng XH,. Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors. J Biol Chem. 2009; 284: 9755-9763.
69. Finnson KW, Parker WL, ten Dijke P, Thorikay M, Philip A,. ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes. J Bone Miner Res. 2008; 23: 896-906. (Pubitemid 351768808)
70. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P,. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. Embo J. 2002; 21: 1743-1753. (Pubitemid 34614630)